News

JBCPL to acquire brands from Sanzyme for Rs 628 crores

The acquisition will mark JBCPL’s entry into the fast-growing probiotics, therapeutic nutraceuticals and reproductive health market with an attractive set of brands

JB Chemicals & Pharmaceuticals Limited (JBCPL) will acquire brands for the Indian market from Sanzyme, a leading player in the probiotics and reproductive health segment in the country. The transaction is valued at Rs 628 crore and is expected to be completed in the next two weeks subject to customary closing formalities.

“We are glad to announce our first acquisition which expands our presence into new Therapeutic areas and also increases the addressable opportunity in the India Pharma market. This is in line with our stated objective of building big brands through category leaders. Sanzyme has been a pioneer in the probiotics segment and we wish to build further on this legacy,” mentioned Nikhil Chopra, CEO & Whole-time Director, JBPCL.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close